nodes	percent_of_prediction	percent_of_DWPC	metapath
Prasugrel—CYP2B6—Thiotepa—urinary bladder cancer	0.229	0.368	CbGbCtD
Prasugrel—ALB—Fluorouracil—urinary bladder cancer	0.0729	0.117	CbGbCtD
Prasugrel—CYP3A4—Thiotepa—urinary bladder cancer	0.0703	0.113	CbGbCtD
Prasugrel—CYP2B6—Cisplatin—urinary bladder cancer	0.0632	0.101	CbGbCtD
Prasugrel—CYP2B6—Doxorubicin—urinary bladder cancer	0.0423	0.068	CbGbCtD
Prasugrel—ALB—Methotrexate—urinary bladder cancer	0.0402	0.0646	CbGbCtD
Prasugrel—CYP2C9—Fluorouracil—urinary bladder cancer	0.0393	0.0631	CbGbCtD
Prasugrel—CYP2C9—Cisplatin—urinary bladder cancer	0.0334	0.0536	CbGbCtD
Prasugrel—CYP3A4—Etoposide—urinary bladder cancer	0.0191	0.0306	CbGbCtD
Prasugrel—CYP3A4—Doxorubicin—urinary bladder cancer	0.013	0.0209	CbGbCtD
Prasugrel—P2RY12—prostate gland—urinary bladder cancer	0.01	0.125	CbGeAlD
Prasugrel—CYP2C19—urine—urinary bladder cancer	0.00819	0.102	CbGeAlD
Prasugrel—P2RY12—epithelium—urinary bladder cancer	0.00735	0.0915	CbGeAlD
Prasugrel—CES2—prostate gland—urinary bladder cancer	0.00638	0.0795	CbGeAlD
Prasugrel—CYP2C9—urine—urinary bladder cancer	0.00635	0.0791	CbGeAlD
Prasugrel—CES2—seminal vesicle—urinary bladder cancer	0.0054	0.0672	CbGeAlD
Prasugrel—CYP3A4—urine—urinary bladder cancer	0.00484	0.0603	CbGeAlD
Prasugrel—CES2—smooth muscle tissue—urinary bladder cancer	0.00452	0.0563	CbGeAlD
Prasugrel—CES2—renal system—urinary bladder cancer	0.00435	0.0542	CbGeAlD
Prasugrel—CES2—urethra—urinary bladder cancer	0.00427	0.0532	CbGeAlD
Prasugrel—CES2—female reproductive system—urinary bladder cancer	0.00348	0.0434	CbGeAlD
Prasugrel—CES2—vagina—urinary bladder cancer	0.00315	0.0392	CbGeAlD
Prasugrel—CES2—lymph node—urinary bladder cancer	0.00204	0.0254	CbGeAlD
Prasugrel—CYP2B6—renal system—urinary bladder cancer	0.00157	0.0195	CbGeAlD
Prasugrel—CYP2C19—vagina—urinary bladder cancer	0.00145	0.0181	CbGeAlD
Prasugrel—CYP2B6—female reproductive system—urinary bladder cancer	0.00126	0.0157	CbGeAlD
Prasugrel—CYP2C9—female reproductive system—urinary bladder cancer	0.00124	0.0155	CbGeAlD
Prasugrel—CYP3A4—renal system—urinary bladder cancer	0.00119	0.0148	CbGeAlD
Prasugrel—ALB—lymph node—urinary bladder cancer	0.00117	0.0145	CbGeAlD
Prasugrel—CYP2B6—vagina—urinary bladder cancer	0.00114	0.0142	CbGeAlD
Prasugrel—Epistaxis—Thiotepa—urinary bladder cancer	0.000967	0.00563	CcSEcCtD
Prasugrel—CYP3A4—female reproductive system—urinary bladder cancer	0.000949	0.0118	CbGeAlD
Prasugrel—Hyperlipidaemia—Doxorubicin—urinary bladder cancer	0.000948	0.00551	CcSEcCtD
Prasugrel—Asthenia—Mitomycin—urinary bladder cancer	0.000933	0.00543	CcSEcCtD
Prasugrel—Haemoglobin—Thiotepa—urinary bladder cancer	0.000925	0.00538	CcSEcCtD
Prasugrel—Haemoptysis—Doxorubicin—urinary bladder cancer	0.000923	0.00537	CcSEcCtD
Prasugrel—Haemorrhage—Thiotepa—urinary bladder cancer	0.000921	0.00536	CcSEcCtD
Prasugrel—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.000909	0.00529	CcSEcCtD
Prasugrel—Urethral disorder—Thiotepa—urinary bladder cancer	0.000903	0.00525	CcSEcCtD
Prasugrel—Diarrhoea—Mitomycin—urinary bladder cancer	0.00089	0.00518	CcSEcCtD
Prasugrel—Neoplasm malignant—Epirubicin—urinary bladder cancer	0.000865	0.00503	CcSEcCtD
Prasugrel—Eye disorder—Thiotepa—urinary bladder cancer	0.00086	0.00501	CcSEcCtD
Prasugrel—Dizziness—Mitomycin—urinary bladder cancer	0.00086	0.005	CcSEcCtD
Prasugrel—Angiopathy—Thiotepa—urinary bladder cancer	0.000835	0.00486	CcSEcCtD
Prasugrel—Immune system disorder—Thiotepa—urinary bladder cancer	0.000832	0.00484	CcSEcCtD
Prasugrel—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.00083	0.00483	CcSEcCtD
Prasugrel—Haematuria—Gemcitabine—urinary bladder cancer	0.000823	0.00479	CcSEcCtD
Prasugrel—Rash—Mitomycin—urinary bladder cancer	0.00082	0.00477	CcSEcCtD
Prasugrel—Dermatitis—Mitomycin—urinary bladder cancer	0.000819	0.00477	CcSEcCtD
Prasugrel—Rectal haemorrhage—Epirubicin—urinary bladder cancer	0.000817	0.00475	CcSEcCtD
Prasugrel—Headache—Mitomycin—urinary bladder cancer	0.000815	0.00474	CcSEcCtD
Prasugrel—Epistaxis—Fluorouracil—urinary bladder cancer	0.0008	0.00465	CcSEcCtD
Prasugrel—Neoplasm malignant—Doxorubicin—urinary bladder cancer	0.0008	0.00465	CcSEcCtD
Prasugrel—Haemoglobin—Gemcitabine—urinary bladder cancer	0.000778	0.00453	CcSEcCtD
Prasugrel—Back pain—Thiotepa—urinary bladder cancer	0.000775	0.00451	CcSEcCtD
Prasugrel—Haemorrhage—Gemcitabine—urinary bladder cancer	0.000775	0.00451	CcSEcCtD
Prasugrel—Nausea—Mitomycin—urinary bladder cancer	0.000773	0.00449	CcSEcCtD
Prasugrel—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000765	0.00445	CcSEcCtD
Prasugrel—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000765	0.00445	CcSEcCtD
Prasugrel—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000763	0.00444	CcSEcCtD
Prasugrel—Haemorrhage—Fluorouracil—urinary bladder cancer	0.000762	0.00443	CcSEcCtD
Prasugrel—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000759	0.00442	CcSEcCtD
Prasugrel—Rectal haemorrhage—Doxorubicin—urinary bladder cancer	0.000756	0.0044	CcSEcCtD
Prasugrel—Anaemia—Thiotepa—urinary bladder cancer	0.000741	0.00431	CcSEcCtD
Prasugrel—Bradycardia—Cisplatin—urinary bladder cancer	0.000735	0.00427	CcSEcCtD
Prasugrel—Leukopenia—Thiotepa—urinary bladder cancer	0.000717	0.00417	CcSEcCtD
Prasugrel—Ecchymosis—Methotrexate—urinary bladder cancer	0.000713	0.00415	CcSEcCtD
Prasugrel—Neoplasm—Methotrexate—urinary bladder cancer	0.000713	0.00415	CcSEcCtD
Prasugrel—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000713	0.00415	CcSEcCtD
Prasugrel—Urethral disorder—Cisplatin—urinary bladder cancer	0.000708	0.00412	CcSEcCtD
Prasugrel—Angiopathy—Gemcitabine—urinary bladder cancer	0.000703	0.00409	CcSEcCtD
Prasugrel—Immune system disorder—Gemcitabine—urinary bladder cancer	0.0007	0.00407	CcSEcCtD
Prasugrel—Cough—Thiotepa—urinary bladder cancer	0.000699	0.00407	CcSEcCtD
Prasugrel—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000698	0.00406	CcSEcCtD
Prasugrel—Hypertension—Thiotepa—urinary bladder cancer	0.000692	0.00403	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000678	0.00394	CcSEcCtD
Prasugrel—Eye disorder—Cisplatin—urinary bladder cancer	0.000675	0.00392	CcSEcCtD
Prasugrel—Ecchymosis—Epirubicin—urinary bladder cancer	0.000667	0.00388	CcSEcCtD
Prasugrel—Neoplasm—Epirubicin—urinary bladder cancer	0.000667	0.00388	CcSEcCtD
Prasugrel—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000653	0.0038	CcSEcCtD
Prasugrel—Back pain—Gemcitabine—urinary bladder cancer	0.000652	0.00379	CcSEcCtD
Prasugrel—Immune system disorder—Cisplatin—urinary bladder cancer	0.000652	0.00379	CcSEcCtD
Prasugrel—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000651	0.00378	CcSEcCtD
Prasugrel—Urethral disorder—Etoposide—urinary bladder cancer	0.000648	0.00377	CcSEcCtD
Prasugrel—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00064	0.00373	CcSEcCtD
Prasugrel—Skin disorder—Thiotepa—urinary bladder cancer	0.000635	0.0037	CcSEcCtD
Prasugrel—Anaemia—Gemcitabine—urinary bladder cancer	0.000623	0.00362	CcSEcCtD
Prasugrel—Eye disorder—Etoposide—urinary bladder cancer	0.000618	0.0036	CcSEcCtD
Prasugrel—Ecchymosis—Doxorubicin—urinary bladder cancer	0.000618	0.00359	CcSEcCtD
Prasugrel—Neoplasm—Doxorubicin—urinary bladder cancer	0.000618	0.00359	CcSEcCtD
Prasugrel—Anaemia—Fluorouracil—urinary bladder cancer	0.000613	0.00356	CcSEcCtD
Prasugrel—Leukopenia—Gemcitabine—urinary bladder cancer	0.000604	0.00351	CcSEcCtD
Prasugrel—Angiopathy—Etoposide—urinary bladder cancer	0.0006	0.00349	CcSEcCtD
Prasugrel—Immune system disorder—Etoposide—urinary bladder cancer	0.000597	0.00347	CcSEcCtD
Prasugrel—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000596	0.00347	CcSEcCtD
Prasugrel—Leukopenia—Fluorouracil—urinary bladder cancer	0.000593	0.00345	CcSEcCtD
Prasugrel—Cough—Gemcitabine—urinary bladder cancer	0.000588	0.00342	CcSEcCtD
Prasugrel—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000584	0.0034	CcSEcCtD
Prasugrel—Hypertension—Gemcitabine—urinary bladder cancer	0.000582	0.00339	CcSEcCtD
Prasugrel—Anaemia—Cisplatin—urinary bladder cancer	0.000581	0.00338	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00057	0.00332	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000565	0.00328	CcSEcCtD
Prasugrel—Fatigue—Thiotepa—urinary bladder cancer	0.000564	0.00328	CcSEcCtD
Prasugrel—Leukopenia—Cisplatin—urinary bladder cancer	0.000563	0.00327	CcSEcCtD
Prasugrel—Back pain—Etoposide—urinary bladder cancer	0.000557	0.00324	CcSEcCtD
Prasugrel—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00055	0.0032	CcSEcCtD
Prasugrel—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000547	0.00318	CcSEcCtD
Prasugrel—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000541	0.00315	CcSEcCtD
Prasugrel—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000539	0.00313	CcSEcCtD
Prasugrel—Pain in extremity—Epirubicin—urinary bladder cancer	0.000536	0.00312	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.000536	0.00312	CcSEcCtD
Prasugrel—Skin disorder—Gemcitabine—urinary bladder cancer	0.000535	0.00311	CcSEcCtD
Prasugrel—Anaemia—Etoposide—urinary bladder cancer	0.000532	0.0031	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000531	0.00309	CcSEcCtD
Prasugrel—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00053	0.00308	CcSEcCtD
Prasugrel—Body temperature increased—Thiotepa—urinary bladder cancer	0.000517	0.00301	CcSEcCtD
Prasugrel—Leukopenia—Etoposide—urinary bladder cancer	0.000515	0.003	CcSEcCtD
Prasugrel—Hypotension—Gemcitabine—urinary bladder cancer	0.000514	0.00299	CcSEcCtD
Prasugrel—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000513	0.00298	CcSEcCtD
Prasugrel—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000506	0.00294	CcSEcCtD
Prasugrel—Hypotension—Fluorouracil—urinary bladder cancer	0.000506	0.00294	CcSEcCtD
Prasugrel—Cough—Etoposide—urinary bladder cancer	0.000502	0.00292	CcSEcCtD
Prasugrel—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000502	0.00292	CcSEcCtD
Prasugrel—Skin disorder—Cisplatin—urinary bladder cancer	0.000498	0.0029	CcSEcCtD
Prasugrel—Hypertension—Etoposide—urinary bladder cancer	0.000497	0.00289	CcSEcCtD
Prasugrel—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000496	0.00288	CcSEcCtD
Prasugrel—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.000496	0.00288	CcSEcCtD
Prasugrel—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000491	0.00285	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000487	0.00283	CcSEcCtD
Prasugrel—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000482	0.00281	CcSEcCtD
Prasugrel—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000482	0.0028	CcSEcCtD
Prasugrel—Hypotension—Cisplatin—urinary bladder cancer	0.000479	0.00279	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000475	0.00276	CcSEcCtD
Prasugrel—Fatigue—Gemcitabine—urinary bladder cancer	0.000474	0.00276	CcSEcCtD
Prasugrel—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00047	0.00273	CcSEcCtD
Prasugrel—Asthenia—Thiotepa—urinary bladder cancer	0.000469	0.00273	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000467	0.00272	CcSEcCtD
Prasugrel—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00046	0.00268	CcSEcCtD
Prasugrel—Dyspnoea—Cisplatin—urinary bladder cancer	0.000457	0.00266	CcSEcCtD
Prasugrel—Skin disorder—Etoposide—urinary bladder cancer	0.000456	0.00265	CcSEcCtD
Prasugrel—Diarrhoea—Thiotepa—urinary bladder cancer	0.000448	0.0026	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000443	0.00258	CcSEcCtD
Prasugrel—Hypotension—Etoposide—urinary bladder cancer	0.000439	0.00255	CcSEcCtD
Prasugrel—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000435	0.00253	CcSEcCtD
Prasugrel—Dizziness—Thiotepa—urinary bladder cancer	0.000433	0.00252	CcSEcCtD
Prasugrel—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000428	0.00249	CcSEcCtD
Prasugrel—Haematuria—Methotrexate—urinary bladder cancer	0.000421	0.00245	CcSEcCtD
Prasugrel—Dyspnoea—Etoposide—urinary bladder cancer	0.000419	0.00244	CcSEcCtD
Prasugrel—Epistaxis—Methotrexate—urinary bladder cancer	0.000416	0.00242	CcSEcCtD
Prasugrel—Rash—Thiotepa—urinary bladder cancer	0.000412	0.0024	CcSEcCtD
Prasugrel—Dermatitis—Thiotepa—urinary bladder cancer	0.000412	0.0024	CcSEcCtD
Prasugrel—Headache—Thiotepa—urinary bladder cancer	0.00041	0.00238	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000406	0.00236	CcSEcCtD
Prasugrel—Body temperature increased—Cisplatin—urinary bladder cancer	0.000405	0.00236	CcSEcCtD
Prasugrel—Fatigue—Etoposide—urinary bladder cancer	0.000405	0.00236	CcSEcCtD
Prasugrel—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000399	0.00232	CcSEcCtD
Prasugrel—Haemoglobin—Methotrexate—urinary bladder cancer	0.000398	0.00232	CcSEcCtD
Prasugrel—Haemorrhage—Methotrexate—urinary bladder cancer	0.000396	0.0023	CcSEcCtD
Prasugrel—Asthenia—Gemcitabine—urinary bladder cancer	0.000395	0.0023	CcSEcCtD
Prasugrel—Haematuria—Epirubicin—urinary bladder cancer	0.000394	0.00229	CcSEcCtD
Prasugrel—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000391	0.00228	CcSEcCtD
Prasugrel—Epistaxis—Epirubicin—urinary bladder cancer	0.00039	0.00227	CcSEcCtD
Prasugrel—Nausea—Thiotepa—urinary bladder cancer	0.000389	0.00226	CcSEcCtD
Prasugrel—Urethral disorder—Methotrexate—urinary bladder cancer	0.000388	0.00226	CcSEcCtD
Prasugrel—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000378	0.0022	CcSEcCtD
Prasugrel—Bradycardia—Epirubicin—urinary bladder cancer	0.000377	0.0022	CcSEcCtD
Prasugrel—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000377	0.00219	CcSEcCtD
Prasugrel—Haemoglobin—Epirubicin—urinary bladder cancer	0.000373	0.00217	CcSEcCtD
Prasugrel—Body temperature increased—Etoposide—urinary bladder cancer	0.000371	0.00216	CcSEcCtD
Prasugrel—Haemorrhage—Epirubicin—urinary bladder cancer	0.000371	0.00216	CcSEcCtD
Prasugrel—Eye disorder—Methotrexate—urinary bladder cancer	0.00037	0.00215	CcSEcCtD
Prasugrel—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00037	0.00215	CcSEcCtD
Prasugrel—Asthenia—Cisplatin—urinary bladder cancer	0.000368	0.00214	CcSEcCtD
Prasugrel—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000366	0.00213	CcSEcCtD
Prasugrel—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000365	0.00212	CcSEcCtD
Prasugrel—Haematuria—Doxorubicin—urinary bladder cancer	0.000364	0.00212	CcSEcCtD
Prasugrel—Urethral disorder—Epirubicin—urinary bladder cancer	0.000363	0.00211	CcSEcCtD
Prasugrel—Epistaxis—Doxorubicin—urinary bladder cancer	0.00036	0.0021	CcSEcCtD
Prasugrel—Angiopathy—Methotrexate—urinary bladder cancer	0.000359	0.00209	CcSEcCtD
Prasugrel—Immune system disorder—Methotrexate—urinary bladder cancer	0.000358	0.00208	CcSEcCtD
Prasugrel—Dizziness—Fluorouracil—urinary bladder cancer	0.000358	0.00208	CcSEcCtD
Prasugrel—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000357	0.00208	CcSEcCtD
Prasugrel—Diarrhoea—Cisplatin—urinary bladder cancer	0.000351	0.00204	CcSEcCtD
Prasugrel—Bradycardia—Doxorubicin—urinary bladder cancer	0.000349	0.00203	CcSEcCtD
Prasugrel—Rash—Gemcitabine—urinary bladder cancer	0.000347	0.00202	CcSEcCtD
Prasugrel—Dermatitis—Gemcitabine—urinary bladder cancer	0.000347	0.00202	CcSEcCtD
Prasugrel—Eye disorder—Epirubicin—urinary bladder cancer	0.000346	0.00202	CcSEcCtD
Prasugrel—Hypersensitivity—Etoposide—urinary bladder cancer	0.000346	0.00201	CcSEcCtD
Prasugrel—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000345	0.00201	CcSEcCtD
Prasugrel—Headache—Gemcitabine—urinary bladder cancer	0.000345	0.00201	CcSEcCtD
Prasugrel—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000343	0.002	CcSEcCtD
Prasugrel—Rash—Fluorouracil—urinary bladder cancer	0.000341	0.00198	CcSEcCtD
Prasugrel—Dermatitis—Fluorouracil—urinary bladder cancer	0.000341	0.00198	CcSEcCtD
Prasugrel—Headache—Fluorouracil—urinary bladder cancer	0.000339	0.00197	CcSEcCtD
Prasugrel—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000339	0.00197	CcSEcCtD
Prasugrel—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000338	0.00197	CcSEcCtD
Prasugrel—Asthenia—Etoposide—urinary bladder cancer	0.000337	0.00196	CcSEcCtD
Prasugrel—Angiopathy—Epirubicin—urinary bladder cancer	0.000336	0.00196	CcSEcCtD
Prasugrel—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000336	0.00196	CcSEcCtD
Prasugrel—Immune system disorder—Epirubicin—urinary bladder cancer	0.000335	0.00195	CcSEcCtD
Prasugrel—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000334	0.00194	CcSEcCtD
Prasugrel—Back pain—Methotrexate—urinary bladder cancer	0.000334	0.00194	CcSEcCtD
Prasugrel—Nausea—Gemcitabine—urinary bladder cancer	0.000327	0.0019	CcSEcCtD
Prasugrel—Rash—Cisplatin—urinary bladder cancer	0.000323	0.00188	CcSEcCtD
Prasugrel—Dermatitis—Cisplatin—urinary bladder cancer	0.000323	0.00188	CcSEcCtD
Prasugrel—Diarrhoea—Etoposide—urinary bladder cancer	0.000322	0.00187	CcSEcCtD
Prasugrel—Nausea—Fluorouracil—urinary bladder cancer	0.000321	0.00187	CcSEcCtD
Prasugrel—Eye disorder—Doxorubicin—urinary bladder cancer	0.000321	0.00186	CcSEcCtD
Prasugrel—Anaemia—Methotrexate—urinary bladder cancer	0.000319	0.00185	CcSEcCtD
Prasugrel—Back pain—Epirubicin—urinary bladder cancer	0.000312	0.00182	CcSEcCtD
Prasugrel—Angiopathy—Doxorubicin—urinary bladder cancer	0.000311	0.00181	CcSEcCtD
Prasugrel—Dizziness—Etoposide—urinary bladder cancer	0.000311	0.00181	CcSEcCtD
Prasugrel—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00031	0.0018	CcSEcCtD
Prasugrel—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000309	0.0018	CcSEcCtD
Prasugrel—Leukopenia—Methotrexate—urinary bladder cancer	0.000309	0.0018	CcSEcCtD
Prasugrel—Nausea—Cisplatin—urinary bladder cancer	0.000305	0.00177	CcSEcCtD
Prasugrel—Cough—Methotrexate—urinary bladder cancer	0.000301	0.00175	CcSEcCtD
Prasugrel—Anaemia—Epirubicin—urinary bladder cancer	0.000298	0.00174	CcSEcCtD
Prasugrel—Rash—Etoposide—urinary bladder cancer	0.000296	0.00172	CcSEcCtD
Prasugrel—Dermatitis—Etoposide—urinary bladder cancer	0.000296	0.00172	CcSEcCtD
Prasugrel—Headache—Etoposide—urinary bladder cancer	0.000294	0.00171	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000292	0.0017	CcSEcCtD
Prasugrel—Leukopenia—Epirubicin—urinary bladder cancer	0.000289	0.00168	CcSEcCtD
Prasugrel—Back pain—Doxorubicin—urinary bladder cancer	0.000289	0.00168	CcSEcCtD
Prasugrel—Cough—Epirubicin—urinary bladder cancer	0.000282	0.00164	CcSEcCtD
Prasugrel—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000281	0.00164	CcSEcCtD
Prasugrel—Nausea—Etoposide—urinary bladder cancer	0.000279	0.00162	CcSEcCtD
Prasugrel—Hypertension—Epirubicin—urinary bladder cancer	0.000279	0.00162	CcSEcCtD
Prasugrel—Anaemia—Doxorubicin—urinary bladder cancer	0.000276	0.00161	CcSEcCtD
Prasugrel—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000276	0.0016	CcSEcCtD
Prasugrel—Skin disorder—Methotrexate—urinary bladder cancer	0.000273	0.00159	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000273	0.00159	CcSEcCtD
Prasugrel—Leukopenia—Doxorubicin—urinary bladder cancer	0.000267	0.00155	CcSEcCtD
Prasugrel—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000263	0.00153	CcSEcCtD
Prasugrel—Hypotension—Methotrexate—urinary bladder cancer	0.000263	0.00153	CcSEcCtD
Prasugrel—Cough—Doxorubicin—urinary bladder cancer	0.000261	0.00152	CcSEcCtD
Prasugrel—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000258	0.0015	CcSEcCtD
Prasugrel—Hypertension—Doxorubicin—urinary bladder cancer	0.000258	0.0015	CcSEcCtD
Prasugrel—Skin disorder—Epirubicin—urinary bladder cancer	0.000256	0.00149	CcSEcCtD
Prasugrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000252	0.00147	CcSEcCtD
Prasugrel—Dyspnoea—Methotrexate—urinary bladder cancer	0.000251	0.00146	CcSEcCtD
Prasugrel—Hypotension—Epirubicin—urinary bladder cancer	0.000246	0.00143	CcSEcCtD
Prasugrel—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000244	0.00142	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000243	0.00141	CcSEcCtD
Prasugrel—Fatigue—Methotrexate—urinary bladder cancer	0.000243	0.00141	CcSEcCtD
Prasugrel—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000239	0.00139	CcSEcCtD
Prasugrel—Skin disorder—Doxorubicin—urinary bladder cancer	0.000237	0.00138	CcSEcCtD
Prasugrel—Dyspnoea—Epirubicin—urinary bladder cancer	0.000235	0.00137	CcSEcCtD
Prasugrel—Hypotension—Doxorubicin—urinary bladder cancer	0.000228	0.00132	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000227	0.00132	CcSEcCtD
Prasugrel—Fatigue—Epirubicin—urinary bladder cancer	0.000227	0.00132	CcSEcCtD
Prasugrel—Body temperature increased—Methotrexate—urinary bladder cancer	0.000222	0.00129	CcSEcCtD
Prasugrel—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000217	0.00126	CcSEcCtD
Prasugrel—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00021	0.00122	CcSEcCtD
Prasugrel—Fatigue—Doxorubicin—urinary bladder cancer	0.00021	0.00122	CcSEcCtD
Prasugrel—Body temperature increased—Epirubicin—urinary bladder cancer	0.000208	0.00121	CcSEcCtD
Prasugrel—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000207	0.00121	CcSEcCtD
Prasugrel—Asthenia—Methotrexate—urinary bladder cancer	0.000202	0.00117	CcSEcCtD
Prasugrel—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000194	0.00113	CcSEcCtD
Prasugrel—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000193	0.00112	CcSEcCtD
Prasugrel—Diarrhoea—Methotrexate—urinary bladder cancer	0.000193	0.00112	CcSEcCtD
Prasugrel—Asthenia—Epirubicin—urinary bladder cancer	0.000189	0.0011	CcSEcCtD
Prasugrel—Dizziness—Methotrexate—urinary bladder cancer	0.000186	0.00108	CcSEcCtD
Prasugrel—Diarrhoea—Epirubicin—urinary bladder cancer	0.00018	0.00105	CcSEcCtD
Prasugrel—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00018	0.00104	CcSEcCtD
Prasugrel—Rash—Methotrexate—urinary bladder cancer	0.000177	0.00103	CcSEcCtD
Prasugrel—Dermatitis—Methotrexate—urinary bladder cancer	0.000177	0.00103	CcSEcCtD
Prasugrel—Headache—Methotrexate—urinary bladder cancer	0.000176	0.00103	CcSEcCtD
Prasugrel—Asthenia—Doxorubicin—urinary bladder cancer	0.000175	0.00102	CcSEcCtD
Prasugrel—Dizziness—Epirubicin—urinary bladder cancer	0.000174	0.00101	CcSEcCtD
Prasugrel—Nausea—Methotrexate—urinary bladder cancer	0.000167	0.000972	CcSEcCtD
Prasugrel—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000167	0.00097	CcSEcCtD
Prasugrel—Rash—Epirubicin—urinary bladder cancer	0.000166	0.000966	CcSEcCtD
Prasugrel—Dermatitis—Epirubicin—urinary bladder cancer	0.000166	0.000965	CcSEcCtD
Prasugrel—Headache—Epirubicin—urinary bladder cancer	0.000165	0.00096	CcSEcCtD
Prasugrel—Dizziness—Doxorubicin—urinary bladder cancer	0.000161	0.000937	CcSEcCtD
Prasugrel—P2RY12—Signaling Pathways—GLI1—urinary bladder cancer	0.00016	0.00128	CbGpPWpGaD
Prasugrel—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000159	0.00127	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000158	0.00126	CbGpPWpGaD
Prasugrel—Nausea—Epirubicin—urinary bladder cancer	0.000156	0.00091	CcSEcCtD
Prasugrel—ALB—Platelet degranulation—IGF1—urinary bladder cancer	0.000155	0.00124	CbGpPWpGaD
Prasugrel—Rash—Doxorubicin—urinary bladder cancer	0.000154	0.000894	CcSEcCtD
Prasugrel—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000154	0.00123	CbGpPWpGaD
Prasugrel—Dermatitis—Doxorubicin—urinary bladder cancer	0.000154	0.000893	CcSEcCtD
Prasugrel—Headache—Doxorubicin—urinary bladder cancer	0.000153	0.000888	CcSEcCtD
Prasugrel—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	0.000148	0.00118	CbGpPWpGaD
Prasugrel—CYP2B6—Biological oxidations—GSTM1—urinary bladder cancer	0.000147	0.00118	CbGpPWpGaD
Prasugrel—CYP2B6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000145	0.00116	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—CREBBP—urinary bladder cancer	0.000145	0.00116	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000145	0.00116	CbGpPWpGaD
Prasugrel—Nausea—Doxorubicin—urinary bladder cancer	0.000145	0.000842	CcSEcCtD
Prasugrel—P2RY12—Hemostasis—IGF1—urinary bladder cancer	0.000143	0.00114	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—IL2—urinary bladder cancer	0.000139	0.00111	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000135	0.00108	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000134	0.00107	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—RHOA—urinary bladder cancer	0.000131	0.00105	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00013	0.00104	CbGpPWpGaD
Prasugrel—P2RY12—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000129	0.00103	CbGpPWpGaD
Prasugrel—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	0.000125	0.000997	CbGpPWpGaD
Prasugrel—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000121	0.000968	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000121	0.000966	CbGpPWpGaD
Prasugrel—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000119	0.000955	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000119	0.000954	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000119	0.000947	CbGpPWpGaD
Prasugrel—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000111	0.000889	CbGpPWpGaD
Prasugrel—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.00011	0.000882	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—IL2—urinary bladder cancer	0.00011	0.00088	CbGpPWpGaD
Prasugrel—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00011	0.000877	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—RBX1—urinary bladder cancer	0.00011	0.000876	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000109	0.00087	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000108	0.000866	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000105	0.000839	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TSC1—urinary bladder cancer	0.000103	0.000823	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—TNF—urinary bladder cancer	0.000101	0.000811	CbGpPWpGaD
Prasugrel—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000101	0.000811	CbGpPWpGaD
Prasugrel—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.0001	0.0008	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—EP300—urinary bladder cancer	9.87e-05	0.000789	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.86e-05	0.000788	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GSTZ1—urinary bladder cancer	9.81e-05	0.000784	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—JAG1—urinary bladder cancer	9.81e-05	0.000784	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—SRC—urinary bladder cancer	9.6e-05	0.000767	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GSTO2—urinary bladder cancer	9.3e-05	0.000744	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NAT1—urinary bladder cancer	9.3e-05	0.000744	CbGpPWpGaD
Prasugrel—ALB—Folate Metabolism—TP53—urinary bladder cancer	8.95e-05	0.000715	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—UGT2B7—urinary bladder cancer	8.51e-05	0.00068	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—RHOA—urinary bladder cancer	8.29e-05	0.000663	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTZ1—urinary bladder cancer	8.26e-05	0.00066	CbGpPWpGaD
Prasugrel—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	8.06e-05	0.000644	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—KRAS—urinary bladder cancer	7.95e-05	0.000635	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—S100B—urinary bladder cancer	7.94e-05	0.000635	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTO2—urinary bladder cancer	7.83e-05	0.000626	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NAT1—urinary bladder cancer	7.83e-05	0.000626	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.7e-05	0.000616	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CYP4B1—urinary bladder cancer	7.66e-05	0.000612	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—RHOA—urinary bladder cancer	7.53e-05	0.000602	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	7.42e-05	0.000593	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	7.28e-05	0.000582	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.28e-05	0.000582	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—SLC19A1—urinary bladder cancer	7.24e-05	0.000578	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.18e-05	0.000574	CbGpPWpGaD
Prasugrel—ALB—Metabolism—UGT2B7—urinary bladder cancer	7.16e-05	0.000573	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—NCOR1—urinary bladder cancer	7.14e-05	0.000571	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—TP53—urinary bladder cancer	7.07e-05	0.000565	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PRSS3—urinary bladder cancer	7.05e-05	0.000564	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	7.03e-05	0.000562	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NAT1—urinary bladder cancer	7.03e-05	0.000562	CbGpPWpGaD
Prasugrel—P2RY12—GPCR downstream signaling—IL2—urinary bladder cancer	6.95e-05	0.000556	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.91e-05	0.000553	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	6.89e-05	0.000551	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	6.76e-05	0.00054	CbGpPWpGaD
Prasugrel—P2RY12—Hemostasis—HRAS—urinary bladder cancer	6.76e-05	0.00054	CbGpPWpGaD
Prasugrel—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.69e-05	0.000535	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.66e-05	0.000532	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—CXCL8—urinary bladder cancer	6.61e-05	0.000528	CbGpPWpGaD
Prasugrel—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.6e-05	0.000527	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CYP4B1—urinary bladder cancer	6.45e-05	0.000515	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	6.43e-05	0.000514	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	6.41e-05	0.000512	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NAT1—urinary bladder cancer	6.41e-05	0.000512	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	6.32e-05	0.000505	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—IL2—urinary bladder cancer	6.32e-05	0.000505	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.31e-05	0.000504	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TERT—urinary bladder cancer	6.29e-05	0.000503	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—IFNA2—urinary bladder cancer	6.15e-05	0.000491	CbGpPWpGaD
Prasugrel—ALB—Metabolism—SLC19A1—urinary bladder cancer	6.09e-05	0.000487	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PRSS3—urinary bladder cancer	5.94e-05	0.000474	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5.86e-05	0.000469	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	5.79e-05	0.000463	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—FGFR3—urinary bladder cancer	5.77e-05	0.000462	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—TYMP—urinary bladder cancer	5.64e-05	0.000451	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—ESR1—urinary bladder cancer	5.61e-05	0.000448	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	5.47e-05	0.000437	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	5.33e-05	0.000426	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	5.3e-05	0.000424	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	5.28e-05	0.000422	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NAT2—urinary bladder cancer	5.1e-05	0.000407	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.99e-05	0.000398	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CREBBP—urinary bladder cancer	4.92e-05	0.000393	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.86e-05	0.000388	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IGF1—urinary bladder cancer	4.85e-05	0.000388	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—EGFR—urinary bladder cancer	4.83e-05	0.000386	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.76e-05	0.00038	CbGpPWpGaD
Prasugrel—ALB—Metabolism—TYMP—urinary bladder cancer	4.74e-05	0.000379	CbGpPWpGaD
Prasugrel—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	4.62e-05	0.00037	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—KRAS—urinary bladder cancer	4.56e-05	0.000365	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.56e-05	0.000364	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.46e-05	0.000356	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—RHOA—urinary bladder cancer	4.45e-05	0.000355	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—RRM2—urinary bladder cancer	4.4e-05	0.000352	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—PLAU—urinary bladder cancer	4.36e-05	0.000349	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NAT2—urinary bladder cancer	4.29e-05	0.000343	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.27e-05	0.000341	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—TYMP—urinary bladder cancer	4.26e-05	0.00034	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.23e-05	0.000338	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.23e-05	0.000338	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—ERBB2—urinary bladder cancer	4.12e-05	0.000329	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.09e-05	0.000327	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—HPGDS—urinary bladder cancer	4.08e-05	0.000326	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—ENO2—urinary bladder cancer	4.08e-05	0.000326	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	3.95e-05	0.000316	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CXCL8—urinary bladder cancer	3.9e-05	0.000312	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.9e-05	0.000311	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.88e-05	0.00031	CbGpPWpGaD
Prasugrel—P2RY12—Signaling by GPCR—HRAS—urinary bladder cancer	3.88e-05	0.00031	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.87e-05	0.000309	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NAT2—urinary bladder cancer	3.85e-05	0.000308	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—IL2—urinary bladder cancer	3.73e-05	0.000298	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.73e-05	0.000298	CbGpPWpGaD
Prasugrel—ALB—Metabolism—RRM2—urinary bladder cancer	3.7e-05	0.000296	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CCND1—urinary bladder cancer	3.64e-05	0.000291	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—CREBBP—urinary bladder cancer	3.6e-05	0.000288	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—IGF1—urinary bladder cancer	3.55e-05	0.000284	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MMP9—urinary bladder cancer	3.53e-05	0.000282	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—CDKN1A—urinary bladder cancer	3.52e-05	0.000281	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.51e-05	0.000281	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—PTEN—urinary bladder cancer	3.51e-05	0.000281	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.48e-05	0.000278	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ENO2—urinary bladder cancer	3.43e-05	0.000274	CbGpPWpGaD
Prasugrel—ALB—Metabolism—HPGDS—urinary bladder cancer	3.43e-05	0.000274	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.41e-05	0.000273	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—EP300—urinary bladder cancer	3.35e-05	0.000268	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTT1—urinary bladder cancer	3.33e-05	0.000266	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.33e-05	0.000266	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.29e-05	0.000263	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NQO1—urinary bladder cancer	3.28e-05	0.000263	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.28e-05	0.000262	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—RHOA—urinary bladder cancer	3.26e-05	0.00026	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—SRC—urinary bladder cancer	3.26e-05	0.00026	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.2e-05	0.000256	CbGpPWpGaD
Prasugrel—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.12e-05	0.000249	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.08e-05	0.000246	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.08e-05	0.000246	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.06e-05	0.000245	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.03e-05	0.000242	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.99e-05	0.000239	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.94e-05	0.000235	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—MYC—urinary bladder cancer	2.92e-05	0.000233	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—EGFR—urinary bladder cancer	2.85e-05	0.000228	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.81e-05	0.000224	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.81e-05	0.000224	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.79e-05	0.000223	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NQO1—urinary bladder cancer	2.77e-05	0.000221	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	2.74e-05	0.000219	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—IL2—urinary bladder cancer	2.73e-05	0.000218	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.72e-05	0.000218	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—KRAS—urinary bladder cancer	2.7e-05	0.000215	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.68e-05	0.000214	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.68e-05	0.000214	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.56e-05	0.000205	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—TYMS—urinary bladder cancer	2.55e-05	0.000204	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	2.52e-05	0.000201	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	2.52e-05	0.000201	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.48e-05	0.000198	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—EP300—urinary bladder cancer	2.45e-05	0.000196	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—GPX1—urinary bladder cancer	2.41e-05	0.000193	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.41e-05	0.000193	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—TP53—urinary bladder cancer	2.4e-05	0.000191	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—SRC—urinary bladder cancer	2.38e-05	0.00019	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	2.37e-05	0.000189	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.34e-05	0.000187	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.32e-05	0.000185	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTP1—urinary bladder cancer	2.31e-05	0.000184	CbGpPWpGaD
Prasugrel—P2RY12—Signaling Pathways—HRAS—urinary bladder cancer	2.29e-05	0.000183	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.26e-05	0.000181	CbGpPWpGaD
Prasugrel—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.23e-05	0.000178	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	2.23e-05	0.000178	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.2e-05	0.000176	CbGpPWpGaD
Prasugrel—ALB—Metabolism—TYMS—urinary bladder cancer	2.14e-05	0.000171	CbGpPWpGaD
Prasugrel—ALB—Metabolism—NCOR1—urinary bladder cancer	2.12e-05	0.000169	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GSTM1—urinary bladder cancer	2.12e-05	0.000169	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.1e-05	0.000168	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.07e-05	0.000165	CbGpPWpGaD
Prasugrel—ALB—Metabolism—GPX1—urinary bladder cancer	2.03e-05	0.000162	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2e-05	0.00016	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2e-05	0.00016	CbGpPWpGaD
Prasugrel—ALB—Metabolism—ERCC2—urinary bladder cancer	1.99e-05	0.000159	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—KRAS—urinary bladder cancer	1.97e-05	0.000158	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.92e-05	0.000154	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.92e-05	0.000153	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.9e-05	0.000152	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.9e-05	0.000152	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.89e-05	0.000151	CbGpPWpGaD
Prasugrel—ALB—Metabolism—MTHFR—urinary bladder cancer	1.87e-05	0.00015	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.85e-05	0.000148	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.85e-05	0.000148	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.83e-05	0.000146	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.82e-05	0.000146	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.8e-05	0.000144	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.8e-05	0.000144	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.79e-05	0.000143	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.75e-05	0.00014	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—TP53—urinary bladder cancer	1.75e-05	0.00014	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.73e-05	0.000139	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.73e-05	0.000139	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.73e-05	0.000139	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.68e-05	0.000134	CbGpPWpGaD
Prasugrel—ALB—Hemostasis—HRAS—urinary bladder cancer	1.68e-05	0.000134	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.66e-05	0.000133	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.63e-05	0.00013	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.53e-05	0.000123	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PPARG—urinary bladder cancer	1.52e-05	0.000121	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.49e-05	0.000119	CbGpPWpGaD
Prasugrel—ALB—Metabolism—CREBBP—urinary bladder cancer	1.46e-05	0.000117	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.42e-05	0.000113	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.36e-05	0.000109	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.31e-05	0.000105	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.24e-05	9.95e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.24e-05	9.94e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—PTEN—urinary bladder cancer	1.24e-05	9.89e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PTGS2—urinary bladder cancer	1.19e-05	9.55e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.19e-05	9.55e-05	CbGpPWpGaD
Prasugrel—CYP2B6—Metabolism—EP300—urinary bladder cancer	1.18e-05	9.44e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.16e-05	9.25e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.14e-05	9.14e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.14e-05	9.14e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.1e-05	8.76e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	8.6e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.07e-05	8.57e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—PTEN—urinary bladder cancer	1.04e-05	8.33e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.01e-05	8.08e-05	CbGpPWpGaD
Prasugrel—ALB—Metabolism—EP300—urinary bladder cancer	9.94e-06	7.94e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	9.78e-06	7.82e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—PTEN—urinary bladder cancer	9.35e-06	7.48e-05	CbGpPWpGaD
Prasugrel—CYP2C19—Metabolism—EP300—urinary bladder cancer	8.92e-06	7.13e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—PTEN—urinary bladder cancer	8.53e-06	6.82e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.2e-06	6.55e-05	CbGpPWpGaD
Prasugrel—CYP2C9—Metabolism—EP300—urinary bladder cancer	8.13e-06	6.5e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.88e-06	6.3e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.45e-06	5.16e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.62e-06	4.5e-05	CbGpPWpGaD
Prasugrel—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.36e-06	4.29e-05	CbGpPWpGaD
